What is nivolumab (often written as “nivolumab pd”)?
Nivolumab is a prescription immunotherapy drug, given by infusion, that targets the PD-1 (programmed death-1) checkpoint on immune cells. By blocking PD-1, it helps T-cells recognize and attack some types of cancer. [1]
What does “PD” mean in the context of nivolumab?
In this context, “PD” refers to the PD-1 pathway (checkpoint “PD-1”), which nivolumab blocks. Nivolumab is sometimes described as a “PD-1 inhibitor.” [1]
What cancers is nivolumab used for?
Nivolumab is used for multiple cancer types, depending on the indication and region’s approvals, including cancers such as melanoma and non-small cell lung cancer, among others. Exact approved uses vary by country and treatment line. [1]
How is nivolumab given and how often?
Nivolumab is administered as an intravenous infusion in a clinical setting. Dosing schedules can differ by regimen and indication. [1]
What side effects are patients commonly concerned about?
Because nivolumab activates the immune system, it can cause immune-mediated side effects (often called “immune-related adverse events”), which may affect organs like the lungs, liver, gut, skin, endocrine glands, and others. If symptoms suggest an immune reaction, clinicians typically hold dosing and treat with immunosuppressive therapy when needed. [1]
Key safety point: what should patients watch for?
Patients are usually advised to report new or worsening symptoms promptly during treatment and after stopping, especially symptoms that could signal inflammation in organs (for example, diarrhea, cough/shortness of breath, rash, severe fatigue, jaundice, or hormone-related symptoms). [1]
Where to find the most accurate answer for your exact need
“PD” could also be part of a local shorthand (for example, “PD” as in a document field, prescription abbreviation, or a specific regimen name). If you share the full phrase or context (a label, prescription line, or clinical note), I can interpret it more precisely.
Sources
[1] https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125554